$AMRN - On a trading lists. Down graded today based on valuation it seems. Our opinion is this has run up big before and after drug approval and has gotten ahead of itself. Wouldn't surprise me to see it drop back under $20 for a while. The company now has to prove it can make money with the drug.* Citi analyst nailed this in our opinion. *Citi downgrades Amarin to Neutral, says strong sales growth priced in.Citi analyst Joel Beatty downgraded Amarin to Neutral from Buy with a price target of $27, up from $23. The stock closed Friday up 12%, or $2.53, to $24.02. The analyst says his new price target reflects a valuation of $11.2B when assuming a diluted share count of 413M. He models for sales of $3.2B in 2024, up from $2.7B previously, reflecting increased confidence in a Vascepa label "that will allow broad use and cost effectiveness that supports taking modest price increases in future years." He believes Vascepa is an effective drug and anticipates sales accelerating significantly over the next year. However, this is now priced into the stock following the recent rally, Beatty tells investors in a research note. $AMRN, Amarin Corporation plc / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page